Penumbra, Inc. (PEN)

From the record

Penumbra, Inc.'s filings since 2017 show 1 warning event: an auditor change (8-K item 4.01, the latest 2024-03-21) (its current reports).

From the record

Penumbra, Inc.'s 10 filed years say what it did: revenue went from $263 million in fiscal 2016 to $1.4 billion in fiscal 2025, up 20.4% a year; it rose in 9 of 9 years; it never fell from a peak; net income was positive in 8 of 10 of those years (its annual reports).

From the record

Over the 3 fiscal years to 2025-12-31, Penumbra, Inc.'s diluted share count grew about 1.3% a year, and dividends and buybacks returned about 20% of its operating cash flow over 3 years (its filed statements). Its officers and directors filed 32 sales (32 under scheduled 10b5-1 plans) and 0 purchases of their own stock on the open market in the year to 2026-10-16 (their Form 4 filings).

From the record

Return on equity: in the fiscal year ended 2025-12-31, Penumbra, Inc. earned about 12 cents of profit for every dollar of shareholders' money, and gross profitability: its products earned about 52 cents per dollar of everything the company owns. Leverage: it owed about 22 cents per dollar of assets, and net share issuance: its share count grew 0.1% over the year (the filed statements).

From the record

Penumbra, Inc.'s standing among 109 graded names in its industry family: revenue of $1.4 billion in fiscal 2025 ranks in the top 16% by size; a net margin of 12.7% ranks in the top 15%; revenue growth of 18.3% a year over the last 3 filed years ranks in the top 41% (its annual reports).

From the record

Penumbra, Inc.'s leadership, from its insiders' filings and its current reports: the chief executive on the record is Elsesser, Adam (CEO, as filed), filing under that title since 2015-09-17, 11.2 years (top 17% of its family); the 11 officers and directors filing in the last fifteen months have been on the record a median of 8.2 years (top 17%); 2 officer or director changes were reported on Form 8-K since 2023-11-13, against the 11 people in charge now (top 9%; fewer changes for each person reads higher) (the Form 4 record, its Form 8-K reports). Years count from a person's first filing in the SEC's data sets, which begin in 2006, so each is a floor.

From the record

Penumbra, Inc.'s room to grow, from the newest filed statements (fiscal 2025): cash of $187 million against no long-term debt tagged leaves 10.2% of its assets as net cash, bottom 49% of its family; cash from operations less capital spending is 12.5% of revenue (top 20%); a gross margin of 67.1% (top 38%); research spending of 6.4% of revenue (bottom 29%) (its annual report).

From the record

Penumbra, Inc.'s growth drivers, from the filed years to fiscal 2025: revenue grew 18.3% a year over the last three filed years against 20.4% over all 10, slowing (bottom 41% of its family); the newest year grew 17.5% (top 36%); research spending grew 4.2% a year (bottom 47%); capital spending grew 48.9% a year (top 11%) (its annual reports). Penumbra, Inc. reported 2 product lines in fiscal 2025: Thrombectomy at $948 million (68%), Embolization at $456 million (33%); 2 of 2 grew against the year before (its annual report).

From the record

Penumbra, Inc.'s newest year against its own record: revenue of $1.4 billion in fiscal 2025 came in 1% below the $1.4 billion its prior three years' pace pointed to (top 44% of its family); net income of $178 million against a prior three-year average of $34 million (top 3%); a net margin of 12.7% against 3.2% before (top 47%) (its annual reports).